2020
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients
Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer And Prostatic Diseases 2020, 24: 414-422. PMID: 32989262, DOI: 10.1038/s41391-020-00291-3.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalLow-risk prostate cancerExternal beam radiotherapyTreatment selection biasOverall survivalRadical prostatectomyProstate cancerOS differenceLow-risk prostate cancer patientsCancer-specific survivalEnd Results (SEER) databaseProstate cancer patientsClinical trial designEffectiveness researchComparative effectiveness researchPropensity-score matchingMethodsThe SurveillanceTreatment guidelinesResults databaseEntire cohortResultsA totalCancer patientsTreatment modalitiesNational registryPatient management
2019
Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups
Killelea BK, Herrin J, Soulos PR, Pollack CE, Forman HP, Yu J, Xu X, Tannenbaum S, Wang SY, Gross CP. Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups. Breast Cancer 2019, 27: 381-388. PMID: 31792804, PMCID: PMC7512133, DOI: 10.1007/s12282-019-01028-4.Peer-Reviewed Original ResearchConceptsPhysician peer groupsLow-income patientsNeedle biopsyOdds ratioHigh-income patientsBreast cancer surgeryMethodsThe SurveillanceCancer surgeryIncome patientsMedicare databaseBiopsy patientsMedicare beneficiariesPatientsBiopsyLow incomeGroupDisparitiesReceiptEnd resultHigher incomeSurgeryPeer groupEpidemiologyFurther workGroup-level effects
2018
Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database
Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research And Treatment 2018, 173: 209-216. PMID: 30242577, DOI: 10.1007/s10549-018-4968-7.Peer-Reviewed Original ResearchConceptsMetastatic-free intervalMetastatic breast cancerInitial breast cancer diagnosisBreast cancer-specific mortalityCancer-specific mortalitySubsequent metastatic diseaseBreast cancer diagnosisMetastatic diseaseFree intervalBreast cancerCancer diagnosisBreast cancer-specific survival ratesMetastatic breast cancer survivalCancer-specific survival ratesDiagnosis of MBCImproved cancer-specific survivalRecurrent metastatic breast cancerCancer-specific survivalEnd Results (SEER) databaseLow tumor gradeBreast cancer survivalChoice of treatmentStratification of patientsMethodsThe SurveillancePurposeThe prevalence
2016
Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy
Wang E, Wang S, Soulos P, Chen R, Kim S, Gross C, Yu J. Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy. Journal Of Radiation Oncology 2016, 6: 295-300. DOI: 10.1007/s13566-016-0269-0.Peer-Reviewed Original ResearchExternal beam radiation therapyIntensity-modulated radiation therapyMental component scoreRadiation therapyProstate cancerEnd Results-Medicare Health Outcomes SurveyEra of IMRTComponent scoresImproved health-related qualityNonmetastatic prostate cancerPhysical component scoreHealth-related qualityHealth Outcomes SurveyStandard of careProstate cancer patientsExternal beam radiotherapyBeam radiation therapyQuality of lifeMethodsThe SurveillanceElderly patientsHRQOL measurementCancer patientsOutcome SurveyBeam radiotherapyLater era
2015
Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER
Yeboa D, Aneja S, Montana G, Roberts K, Yu J. Historical trends of radiotherapy use in prevalent malignancies over 38 years in SEER. Journal Of Radiation Oncology 2015, 4: 11-17. DOI: 10.1007/s13566-015-0182-y.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProstate cancerRadiation therapyEnd Results (SEER) databaseAmerican Joint CommitteeBreast cancer treatmentUse of RTInitial therapyMethodsThe SurveillanceRT receiptNonmetastatic patientsResults databaseCommon malignancyTherapy utilizationColorectal cancerLung cancerPrevalent malignancyCancer sitesRadiotherapy useHigh incidenceMedical treatmentJoint CommitteeDisease sitesPersistent decreaseTherapy
2013
Surgical Resection in Hepatocellular Carcinoma Patients with Minimal Background Fibrosis: A Strategy in the Era of Organ Shortage
Groeschl R, Clark Gamblin T, Turaga K. Surgical Resection in Hepatocellular Carcinoma Patients with Minimal Background Fibrosis: A Strategy in the Era of Organ Shortage. Annals Of Surgical Oncology 2013, 20: 2043-2048. PMID: 23334253, DOI: 10.1245/s10434-012-2857-6.Peer-Reviewed Original ResearchConceptsEra of organ shortageExtended resectionHepatocellular carcinoma patientsHepatocellular carcinomaSurgical resectionLocal ablationSegmental resectionHepatocellular carcinoma treated with surgical resectionEnd Results databaseNonmetastatic hepatocellular carcinomasOrgan shortageOutcomes of patientsFibrosis grades 0BackgroundSurgical therapyUnresectable diseaseMethodsThe SurveillanceCarcinoma patientsResults databaseMinimal fibrosisGrade 0Curative approachResectionSurvival advantageExtensive fibrosisTransplantation
2012
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis
Tsao C, Small A, Kates M, Moshier E, Wisnivesky J, Gartrell B, Sonpavde G, Godbold J, Palese M, Hall S, Oh W, Galsky M. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World Journal Of Urology 2012, 31: 1535-1539. PMID: 23223962, PMCID: PMC4744480, DOI: 10.1007/s00345-012-1001-3.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaVEGFR-TKIsRenal cell carcinomaLogistic regression analysisCytoreductive nephrectomyCell carcinomaTreatment of metastatic renal cell carcinomaVascular endothelial growth factor tyrosine kinase inhibitorEra of targeted therapyMultivariate logistic regression analysisEnd Results registryPhase III trialsTyrosine kinase inhibitorsLevel 1 evidenceAssociated with decreased useSEER analysisRegression analysisMethodsThe SurveillanceIII trialsTreatment eraTreatment modalitiesOlder patientsPatient characteristicsKinase inhibitorsRandomized trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply